700 related articles for article (PubMed ID: 33151168)
1. Sitagliptin: a potential drug for the treatment of COVID-19?
Bardaweel SK; Hajjo R; Sabbah DA
Acta Pharm; 2021 Jun; 71(2):175-184. PubMed ID: 33151168
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
[TBL] [Abstract][Full Text] [Related]
3. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin.
Mozafari N; Azadi S; Mehdi-Alamdarlou S; Ashrafi H; Azadi A
Med Hypotheses; 2020 Oct; 143():110111. PubMed ID: 32721805
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
Solerte SB; Di Sabatino A; Galli M; Fiorina P
Acta Diabetol; 2020 Jul; 57(7):779-783. PubMed ID: 32506195
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 and diabetes: Can DPP4 inhibition play a role?
Iacobellis G
Diabetes Res Clin Pract; 2020 Apr; 162():108125. PubMed ID: 32224164
[No Abstract] [Full Text] [Related]
8. Impact of Sitagliptin on Non-diabetic Covid-19 Patients.
Al-Kuraishy HM; Al-Gareeb AI; Qusty N; Alexiou A; Batiha GE
Curr Mol Pharmacol; 2022; 15(4):683-692. PubMed ID: 34477540
[TBL] [Abstract][Full Text] [Related]
9. Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections.
Mani S; Kaur A; Jakhar K; Kumari G; Sonar S; Kumar A; Das S; Kumar S; Kumar V; Kundu R; Pandey AK; Singh UP; Majumdar T
Int J Biol Macromol; 2023 Aug; 245():125444. PubMed ID: 37385308
[TBL] [Abstract][Full Text] [Related]
10. Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
Alomair BM; Al-Kuraishy HM; Al-Buhadily AK; Al-Gareeb AI; De Waard M; Elekhnawy E; Batiha GE
Inflammopharmacology; 2022 Dec; 30(6):2411-2415. PubMed ID: 36180664
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities.
Varela-Calviño R; Rodríguez-Quiroga M; Dias Carvalho P; Martins F; Serra-Roma A; Vázquez-Iglesias L; Páez de la Cadena M; Velho S; Cordero OJ
IUBMB Life; 2021 May; 73(5):761-773. PubMed ID: 33615655
[TBL] [Abstract][Full Text] [Related]
12. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
Stoian AP; Papanas N; Prazny M; Rizvi AA; Rizzo M
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):494-496. PubMed ID: 32618198
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.
Drucker DJ
Endocr Rev; 2020 Jun; 41(3):. PubMed ID: 32294179
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
15. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19.
Chen CF; Chien CH; Yang YP; Chou SJ; Wang ML; Huo TI; Lin CC
J Chin Med Assoc; 2020 Aug; 83(8):710-711. PubMed ID: 32349031
[TBL] [Abstract][Full Text] [Related]
16. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice.
Kawasaki T; Chen W; Htwe YM; Tatsumi K; Dudek SM
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L834-L845. PubMed ID: 30188745
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibition prevents vascular dysfunction induced by β-adrenergic hyperactivity.
Oliveira BC; Marques VB; Brun BF; de Oliveira E Silva HM; Freitas Soares Melo S; Oliveira EM; Dos Santos L; Barauna VG
Biomed Pharmacother; 2019 May; 113():108733. PubMed ID: 30861410
[TBL] [Abstract][Full Text] [Related]
19. DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19?
Strollo R; Pozzilli P
Diabetes Metab Res Rev; 2020 Nov; 36(8):e3330. PubMed ID: 32336007
[TBL] [Abstract][Full Text] [Related]
20. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target.
Wang K; Zhang Z; Hang J; Liu J; Guo F; Ding Y; Li M; Nie Q; Lin J; Zhuo Y; Sun L; Luo X; Zhong Q; Ye C; Yun C; Zhang Y; Wang J; Bao R; Pang Y; Wang G; Gonzalez FJ; Lei X; Qiao J; Jiang C
Science; 2023 Aug; 381(6657):eadd5787. PubMed ID: 37535747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
